Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa
- PMID: 33294807
- PMCID: PMC7700892
- DOI: 10.1016/j.eclinm.2020.100582
Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa
Abstract
Background: Implementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high Loa loa microfilarial densities (MFD). We developed the first statistical models enabling prediction of SAE risk in individuals with a given MFD.
Methods: We used individual participant data from two trials conducted in loiasis-onchocerciasis co-endemic areas in Cameroon. among the 10 506 ivermectin-treated subjects included in the analysis, 38 (0·36%) developed an ivermectin-related SAE. To predict individual-level risk of SAE, we developed mixed multivariate logistic models including subjects' sex, age, pre-treatment L loa and Mansonella perstans MFDs, and study region.
Findings: The models predicted that regardless of sex, about 1% of people with 20 000 L loa microfilariae per millilitre of blood (mf/mL), 10% of people with 50 000 mf/mL and about one third of those with 100 000 mf/mL will develop an SAE. For a given MFD, males have a three-fold higher risk of developing an SAE than females.
Interpretation: By enabling the prediction of post-ivermectin SAE risk in communities with known distribution of L loa MFDs, our results can guide decisions on the choice of ivermectin-based treatment strategies. They also predict that 37 SAEs were prevented in 2015 by using a Test-and-Treat strategy in the Okola District of Cameroon.
Funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Institut de Recherche pour le Développement; Mectizan Donation Program; Bill & Melinda Gates Foundation.
Keywords: Africa; Loiasis; Serious adverse events.
© 2020 The Authors.
Conflict of interest statement
We declare no competing interests.
Figures


Similar articles
-
Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.Lancet Infect Dis. 2020 Jan;20(1):102-109. doi: 10.1016/S1473-3099(19)30554-7. Epub 2019 Oct 31. Lancet Infect Dis. 2020. PMID: 31676244 Free PMC article.
-
Evaluating post-treatment Loa loa microfilarial densities to classify serious adverse events caused by ivermectin: a retrospective analysis.Lancet Microbe. 2023 Feb;4(2):e93-e101. doi: 10.1016/S2666-5247(22)00331-7. Epub 2023 Jan 13. Lancet Microbe. 2023. PMID: 36646105
-
Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.PLoS Negl Trop Dis. 2025 Mar 28;19(3):e0012957. doi: 10.1371/journal.pntd.0012957. eCollection 2025 Mar. PLoS Negl Trop Dis. 2025. PMID: 40153701 Free PMC article.
-
Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis.Parasit Vectors. 2017 Apr 5;10(1):172. doi: 10.1186/s13071-017-2103-y. Parasit Vectors. 2017. PMID: 28381279 Free PMC article. Review.
-
Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection.Ann Trop Med Parasitol. 1997 Sep;91(6):573-89. doi: 10.1080/00034989760671. Ann Trop Med Parasitol. 1997. PMID: 9425360 Review.
Cited by
-
Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action.Indian Dermatol Online J. 2021 Jul 14;12(4):500-514. doi: 10.4103/idoj.idoj_298_21. eCollection 2021 Jul-Aug. Indian Dermatol Online J. 2021. PMID: 34430453 Free PMC article. Review.
-
Characterising co-infections with Plasmodium spp., Mansonella perstans or Loa loa in asymptomatic children, adults and elderly people living on Bioko Island using nucleic acids extracted from malaria rapid diagnostic tests.PLoS Negl Trop Dis. 2022 Jan 31;16(1):e0009798. doi: 10.1371/journal.pntd.0009798. eCollection 2022 Jan. PLoS Negl Trop Dis. 2022. PMID: 35100277 Free PMC article.
-
Diagnostic performance of capillary and venous blood samples in the detection of Loa loa and Mansonella perstans microfilaraemia using light microscopy.PLoS Negl Trop Dis. 2021 Aug 16;15(8):e0009623. doi: 10.1371/journal.pntd.0009623. eCollection 2021 Aug. PLoS Negl Trop Dis. 2021. PMID: 34398886 Free PMC article.
-
Cases of Loiasis Among a Congolese Family: Screening for Loiasis Among Newly Arrived Refugees From Endemic Areas.J Nurse Pract. 2023 Mar;19(3):104505. doi: 10.1016/j.nurpra.2022.11.015. Epub 2023 Jan 27. J Nurse Pract. 2023. PMID: 36936748 Free PMC article.
-
Onchocerciasis drug development: from preclinical models to humans.Parasitol Res. 2021 Dec;120(12):3939-3964. doi: 10.1007/s00436-021-07307-4. Epub 2021 Oct 13. Parasitol Res. 2021. PMID: 34642800 Free PMC article. Review.
References
-
- Gardon J., Gardon-Wendel N., Demanga-Ngangue Kamgno J, Chippaux J.P., Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350:18–22. - PubMed
-
- World Health Organization. Report of the second Meeting of the WHO Onchocerciasis Technical Advisory Subgroup, WHO, Geneva, Switzerland, 12-14 February 2018. WHO/CDS/NTD/PCT/2018.11. 2018 https://apps.who.int/iris/bitstream/handle/10665/277238/WHO-CDS-NTD-PCT-....
LinkOut - more resources
Full Text Sources